Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.78 |
| ▸ | GAA | P10253 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13299621 | 0.95 | KMT2A (0.71) | KMT2AGAAALDH1A1CA2CA9 | |
| SCHEMBL18503840 | 0.88 | KMT2A (1.00) | KMT2AGAAALDH1A1CA2CA9 | |
| SCHEMBL1939652 | 0.86 | KMT2A (0.73) | KMT2AGAAALDH1A1CA2CA9 | |
| SCHEMBL11230795 | 0.86 | KMT2A (0.73) | KMT2AGAAALDH1A1CA2CA9 | |
| SCHEMBL23703133 | 0.86 | KMT2A (0.73) | KMT2AGAAALDH1A1CA2CA9 | |
| SCHEMBL25061922 | 0.86 | KMT2A (0.73) | KMT2AGAAALDH1A1HSD11B1MAPT | |
| SCHEMBL1464359 | 0.86 | KMT2A (0.73) | KMT2AGAAALDH1A1HSD11B1NPSR1 | |
| SCHEMBL2024141 | 0.86 | KMT2A (0.73) | KMT2AGAAALDH1A1CA9RECQL | |
| SCHEMBL5860960 | 0.85 | KMT2A (0.71) | KMT2AGAAALDH1A1HSD11B1MAPT | |
| SCHEMBL8249922 | 0.85 | KMT2A (0.71) | KMT2AGAAALDH1A1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | GONGWIN BIOPHARM CO., LTD (TW) | 2023-10-12 | — | — | US | disclosed |
| US-11752118-B2 | Method for treating melanoma | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-20230054928-A1 | METHOD FOR PREPARING CARBONYL SULFONE | SOOCHOW UNIVERSITY (CN) | 2023-02-23 | — | — | US | disclosed |
| US-10905769-B2 | Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2021-02-02 | — | — | US | disclosed |
| CN-111808003-A | Preparation method of thioether | 甘肃农业大学 | 2020-10-23 | — | — | CN | disclosed |
| CN-110054574-A | A kind of synthetic method of fluorenylmethyloxycarbonyl -2,3- dehydrogenation-valine | 上海吉奉生物科技有限公司 | 2019-07-26 | — | — | CN | disclosed |
| CN-102786373-B | A kind of synthetic method of diazomethane compound | SHENZHEN IPI BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2016-01-13 | — | — | CN | disclosed |
| CN-102786373-A | Synthetic method of diazomethane compound | SHENZHEN IPI BIOLOG TECHNOLOGY CO LTD | 2012-11-21 | — | — | CN | disclosed |
| US-6342508-B1 | ENZYME INHIBITORS FOR PROTECTION OF CONNECTIVE TISSUES | AMERICAN CYANAMID COMPANY | 2002-01-29 | — | — | US | disclosed |
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-01-17 | — | — | US | disclosed |
| US-6331563-B1 | LOW MOLECULAR WEIGHT, NON-PEPTIDE INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME; TREATING ARTHRITIS, TUMOR METASTASIS, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, INSULIN RESISTANCE | WYETH HOLDINGS CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-6288086-B1 | COMPOUNDS SUCH AS 1-METHYL-4-(4-BUTOXY-BENZENESULFONYL) -PIPERIDINE-4-CARBOXYLIC ACID HYDROXYAMIDE USED TO TREAT ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, ETC.; LOW MOLECULAR WEIGHT AND NON-PEPTIDAL | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | disclosed |
| US-6172057-B1 | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2001-01-09 | — | — | US | disclosed |
| EP-1054858-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999042436-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
| US-5597776-A | ANTAGONIST FOR HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-28 | — | — | US | disclosed |
| US-5145611-A | Diabetes | BOEHRINGER MANNHEIM GMBH (DE) | 1992-09-08 | — | — | US | disclosed |
| US-4326066-A | Triazolyl coumarin compounds, processes for their preparation and their use as whiteners and laser dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1982-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | LIPE, FABP4, LIPA | KMT2A 2032/4885GAA 128/4885ALDH1A1 728/4885 |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, PGM2 | KMT2A 2181/4885GAA 9/4885ALDH1A1 326/4885 |
| US-10905769-B2 | Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use | PLK1, POLR1E, POLK | KMT2A 1885/4885GAA 2860/4885ALDH1A1 4834/4885 |
| US-20230054928-A1 | METHOD FOR PREPARING CARBONYL SULFONE | TST, CBS, STS | KMT2A 2093/4885GAA 707/4885ALDH1A1 297/4885 |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | TP53, MCL1, TOP2B | KMT2A 1380/4885GAA 1313/4885ALDH1A1 381/4885 |
| US-11752118-B2 | Method for treating melanoma | TYR, MITF, BRAF | KMT2A 1442/4885GAA 552/4885ALDH1A1 528/4885 |
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | KMT2A 3103/4885GAA 351/4885ALDH1A1 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.